Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAINTAIN-POP: EXL01 for prevention of post-operative recurrence of Crohn's disease
2024-511357-22-00Phase 2Authorised
- Sponsor
- GETAID
- Start
- Jan 2025
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing EXL01 with EXL01 matching placebo (2 arms). Primary endpoint: Distribution of modified Rutgeerts score at Week 24/EOT. Planned start Jan 2025; status: authorised.
02
Drugs
exl01
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-511357-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511357-22-00.